Hepatitis

The Pharmacy Times® Hepatitis resource center provides clinical news and articles, pertaining to the Food and Drug Administration approved therapies to treat Hepatitis A, B, and C. Additionally, pharmacists will find coverage from pertinent conferences and meetings, videos, podcasts, and other associated content.

What can we help you find?

First Treatment for All Genotypes of Hepatitis C in Children Receives FDA Approval

This drug was previously approved, in 2017, to treat HCV in adults.

Study Examines HCV Retreatment Regimen in Patients with Previous Virologic Failure

Glecaprevir/pibrentasvir (G/P) plus sofosbuvir and ribavirin can potentially treat patients who experienced previous virologic failure following G/P therapy.

Direct-acting Antivirals Show Real World Efficacy in HCV/HIV Coinfection

HIV infection is associated with higher rates of hepatitis C replication.

How Does Sustained Virologic Response of Hepatitis C Affect Long-Term Health?

An increasing number of patients with decompensated cirrhosis are receiving direct-acting antiviral treatment and attaining sustained virologic response of hepatitis C, however, their long-term outcomes are unclear.

Patients With Cancer Treated for Hepatitis C Still Suitable for Chemo Trials

Study finds chronic hepatitis C virus infection should not delay the initiation of an urgent cancer therapy.

Eradicating HCV, HBV Becoming Realistic Goal

Achievable steps could be taken to reach the World Health Organization goal of eliminating hepatitis B and C virus infections as public health threats by 2030.

Potential Hepatitis C Vaccine Could Help Eradicate Disease

A novel vaccine to prevent hepatitis C infection has been tested in Baltimore and at two other sites in the United States.

Hepatitis C, HIV Drugs Remain Number One in Outpatient Medicaid Spending

Kaiser Family Foundation analysis examines Medicaid outpatient prescription drug utilization and spending before rebates.

HCV: Direct-Acting Antivirals May Reduce Mortality, Liver Cancer Risk

The study was the first to compare patients with hepatitis C treated with direct-acting antiviral drugs and those untreated for long-term risks.

Study: Highly Cost Effective to Screen Pregnant Women for Hepatitis C

Because pregnancy is one of the few times individuals are in contact with the health system and covered by health insurance, there is a cost-effective opportunity to screen for hepatitis C virus.

Gastric Acid Drugs Not Found to Inhibit Efficacy of Hepatitis C Treatment

Study finds that glecaprevir/pibrentasvir pan-genotypic efficacy for hepatitis C virus is achieved regardless of whether patients are concurrently receiving gastric acid-reducing drugs.

Large Study Supports Direct-Acting Antiviral Link to Reduced Mortality, Liver Cancer Risk in HCV

New research supports the use of direct-acting antiviral therapy for all individuals with chronic hepatitis C infection.

The Pharmacy Times® Hepatitis condition center provides a source of all the latest clinical information, with articles covering updates from the robust pipeline of novel diabetes therapies, and the newest data from all phases of clinical trials and studies in the space.

Among its other resources are a wealth of videos including interviews with thought leaders and experts in the inflammatory liver disease, and moderated Peer Exchange panels featuring the world’s leading hepatologists and gastroenterologists discussing best practices and key methods for treating complex cases, utilizing the newest therapies, examining the issues and challenges of treating the disease, and much more.